Full-Time
Posted on 7/10/2024
Develops precision oncology treatments for cancer
No salary listed
Junior, Mid
Boston, MA, USA
Upload your resume to see how it matches 2 keywords from the job description.
PDF, DOC, DOCX, up to 4 MB
Scorpion Therapeutics develops precision oncology treatments aimed at targeting specific cancer drivers. Their drugs are designed to interact with validated cancer targets, enhancing selectivity and improving safety and effectiveness. The company collaborates with larger pharmaceutical firms for distribution, allowing them to focus on drug development while leveraging established networks. Their revenue comes from partnerships, including upfront payments and royalties from drug sales. Scorpion Therapeutics is distinguished by its expert team in various scientific fields and a strong emphasis on a collaborative work culture. The goal is to provide effective cancer treatments to healthcare providers and patients globally.
Company Size
51-200
Company Stage
Series C
Total Funding
$420M
Headquarters
Boston, Massachusetts
Founded
2020
Help us improve and share your feedback! Did you find this helpful?
In conjunction with the funding, Lightspeed Venture partner Shelley Chu will become an investor board member and Frazier Life Sciences managing partner Albert Cha will join the board of Scorpion as an observer.
Scorpion Therapeutics, a Boston, MA-based clinical-stage oncology company, raised $150M in Series C funding
Scorpion Therapeutics appoints Adam Friedman, M.D., Ph.D., as Chief Executive Officer and expands Leadership Team.
Streit joined Scorpion in 2022 from Sanofi, where he had most recently served as vice president and senior project head.
Scorpion Therapeutics appoints precision medicine leader Jeff Albers as strategic advisor.